Library · Immune · Antimicrobial and wound healing agent
LL-37 (CAP-18)
hCAP-18, CAMP, Cathelicidin LL-37, Human Cathelicidin, FALL-39
Naturally occurring 37-amino-acid antimicrobial peptide from the human cathelicidin family, discovered in 1995, active against bacteria, viruses, and fungi as part of innate immunity. Also promotes wound healing, resolves inflammation, and attracts immune cells; synthetic versions are being studied for resistant infections and chronic wounds.
Research score 75/100. Reference only, not a dose.
- Immune Boosting
- Anti-bacterial
- Anti-viral
- Wound Healing
- Inflammation Resolution
- Anti-inflammatory
- US status
- Research Chemical
- Approval
- Research Chemical Only
- Evidence
- Human Cathelicidin antimicrobial peptide. Promotes wound healing and modulates immunity. Investigational for venous leg ulcers.
- Research score
- 75 / 100
- Indication
- Research Only - No Medical Indication
- Origin
- Sweden
- Source category
- Immune System
- Status group
- Research chemical
Mechanism
Disrupts microbial membranes via electrostatic attraction and pore formation; also binds FPRL1 and P2X7 receptors on immune cells to recruit neutrophils, monocytes, and T cells, activates dendritic cells via TLR signaling, aids epithelial migration through EGFR transactivation, and neutralizes bacterial endotoxin.
Safety file
Narrow therapeutic window due to toxicity at high concentrations; may worsen autoimmune conditions like psoriasis or lupus through inflammation. Topical use is safe; systemic use is limited by toxicity.
- Local injection site reactions
- Temporary immune system activation
- Potential inflammatory response